Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging

Focal therapy of prostate cancer (PCa) is currently of great interest, but a metric of success. other than biopsy, is not yet available. In a patient with a repeatedly negative MRI and negative systematic biopsies, a scan employing the radioisotope (68)Ga-PSMA-11 PET/CT identified a PSMA-avid hotspo...

Descripción completa

Detalles Bibliográficos
Autores principales: Topoozian, Mark, Calais, Jeremie, Felker, Ely, Sisk, Anthony, Gonzalez, Samantha, Lee, Sean J., Marks, Leonard S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285561/
https://www.ncbi.nlm.nih.gov/pubmed/37358989
http://dx.doi.org/10.1016/j.eucr.2023.102461
Descripción
Sumario:Focal therapy of prostate cancer (PCa) is currently of great interest, but a metric of success. other than biopsy, is not yet available. In a patient with a repeatedly negative MRI and negative systematic biopsies, a scan employing the radioisotope (68)Ga-PSMA-11 PET/CT identified a PSMA-avid hotspot in the prostate. PSMA-guided biopsy confirmed the diagnosis of a clinically-significant PCa. Following ablation of the lesion with high-intensity focused ultrasound (HIFU), the PSMA-avid lesion disappeared and targeted biopsy confirmed a fibrotic scar with no residual cancer. PSMA imaging may have a role in guiding diagnosis, focal ablation, and follow-up of men with PCa.

Ejemplares similares